Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.

Yu MY, Kim YC, Koo HS, Chin HJ.

PLoS One. 2017 Nov 20;12(11):e0188375. doi: 10.1371/journal.pone.0188375. eCollection 2017.

2.

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.

Du B, Jia Y, Zhou W, Min X, Miao L, Cui W.

BMC Nephrol. 2017 Jul 19;18(1):245. doi: 10.1186/s12882-017-0647-x.

3.

Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial.

Hirai K, Ookawara S, Kitano T, Miyazawa H, Ito K, Ueda Y, Kaku Y, Hoshino T, Mori H, Yoshida I, Kubota K, Yamaji Y, Takeda T, Nakamura Y, Tabei K, Morishita Y.

Kidney Res Clin Pract. 2017 Jun;36(2):159-166. doi: 10.23876/j.krcp.2017.36.2.159. Epub 2017 Jun 30.

4.

Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.

Coppo R.

J Am Soc Nephrol. 2017 Jan;28(1):25-33. doi: 10.1681/ASN.2016060647. Epub 2016 Sep 26. Review.

5.

Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring.

Konvalinka A, Batruch I, Tokar T, Dimitromanolakis A, Reid S, Song X, Pei Y, Drabovich AP, Diamandis EP, Jurisica I, Scholey JW.

Clin Proteomics. 2016 Aug 5;13:16. doi: 10.1186/s12014-016-9117-x. eCollection 2016.

6.

Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Rasche FM, Keller F, Rasche WG, Schiekofer S, Boldt A, Sack U, Fahnert J.

Clin Exp Immunol. 2016 Nov;186(2):115-133. doi: 10.1111/cei.12823. Epub 2016 Sep 8. Review.

7.

Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.

Jo YI, Na HY, Moon JY, Han SW, Yang DH, Lee SH, Park HC, Choi HY, Lim SD, Kie JH, Lee YK, Shin SK.

Korean J Intern Med. 2016 Mar;31(2):335-43. doi: 10.3904/kjim.2014.266. Epub 2016 Feb 15.

8.

Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine.

Kaneko T, Arai M, Ikeda M, Morita M, Watanabe Y, Hirama A, Shimizu A, Tsuruoka S.

Int Urol Nephrol. 2015 Nov;47(11):1823-30. doi: 10.1007/s11255-015-1118-6. Epub 2015 Oct 3.

9.

New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.

Magistroni R, D'Agati VD, Appel GB, Kiryluk K.

Kidney Int. 2015 Nov;88(5):974-89. doi: 10.1038/ki.2015.252. Epub 2015 Sep 16. Review.

10.

Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model.

Sexton S, Tulowitzki R, Jones CA, Shah S, Hajduczok G, Gross KW, Panesar M.

Clin Exp Nephrol. 2016 Apr;20(2):162-8. doi: 10.1007/s10157-015-1141-z. Epub 2015 Jul 3.

11.

The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism.

Szeto CC, Li PK.

NDT Plus. 2009 Jun;2(3):205-12. doi: 10.1093/ndtplus/sfp034. Epub 2009 Mar 24.

12.

The effect of angiotensin type 1 receptor blockade on adhesion molecules in patients with IgA nephropathy.

Xydakis D, Papadogiannakis A, Sfakianaki M, Kostakis K, Sfyridakh A.

NDT Plus. 2008 Oct;1(5):377. doi: 10.1093/ndtplus/sfn096. No abstract available.

13.

Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.

Kou J, Wu J, Yang HT, He YN, Fang JA, Deng YY, Xie YS, Nie LF, Lin HL, Cai GY, Chen XM.

Trials. 2014 Dec 5;15:479. doi: 10.1186/1745-6215-15-479.

14.

Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus.

[No authors listed]

Kidney Int Suppl (2011). 2012 Dec;2(5):357-362. No abstract available.

15.

Chapter 10: Immunoglobulin A nephropathy.

[No authors listed]

Kidney Int Suppl (2011). 2012 Jun;2(2):209-217. No abstract available.

16.

Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.

Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

Am J Kidney Dis. 2014 Jul;64(1):74-85. doi: 10.1053/j.ajkd.2014.02.020. Epub 2014 Apr 29.

17.

The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.

Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK.

PLoS One. 2013 May 10;8(5):e62736. doi: 10.1371/journal.pone.0062736. Print 2013.

18.

Nationwide survey on current treatments for IgA nephropathy in Japan.

Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, Matsuo S, Tomino Y.

Clin Exp Nephrol. 2013 Dec;17(6):827-33. doi: 10.1007/s10157-013-0779-7. Epub 2013 Mar 22.

19.

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.

Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL.

Am J Hypertens. 2013 Mar;26(3):424-41. doi: 10.1093/ajh/hps038. Epub 2013 Jan 7.

20.

Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator.

Hamano Y, Okude T, Yokosuka O, Ogawa M.

Nephron Extra. 2011 Jan;1(1):78-90. doi: 10.1159/000331704. Epub 2011 Sep 22.

Supplemental Content

Support Center